Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT)
5.6200
-0.0800 (-1.40%)
NASDAQ · Last Trade: Sep 16th, 2:22 PM EDT
Detailed Quote
Previous Close
5.700
Open
5.650
Bid
5.540
Ask
5.710
Day's Range
5.400 - 6.000
52 Week Range
0.6400 - 6.260
Volume
125,995
Market Cap
25.63M
PE Ratio (TTM)
-4.357
EPS (TTM)
-1.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
170,700
Chart
About Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT)
Lixte Biotech Holdings is a biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other life-threatening diseases. The company specializes in cell death pathways, aiming to identify and advance drug candidates that can effectively target and disrupt these pathways to induce cancer cell death. By leveraging its proprietary technology and research, Lixte seeks to bring innovative solutions to the market, contributing to the advancement of cancer treatment and improving patient outcomes. Read More
BOCA RATON, FL / ACCESS Newswire / September 16, 2025 / For a small-cap biotech, the headlines often center on fundraising, partnerships, or meeting exchange requirements. But every so often, the spotlight shifts to the science itself. Especially when it's the kind with the potential to rewrite how cancer is treated. That is where LIXTE Biotechnology Holdings (NASDAQ:LIXT) finds itself today.
BOCA RATON, FL / ACCESS Newswire / September 15, 2025 / For most small-cap biotechs, the summer months mean quiet trial work and the occasional conference slide deck. LIXTE Biotechnology Holdings (NASDAQ:LIXT) had other plans. Since June 2025, the company has rewritten its playbook, refreshing leadership, raising capital, securing scientific validation, and even moving part of its treasury into digital assets. If LB-100 is the scientific spark, then the corporate fire LIXTE is lighting around it may prove just as fascinating.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.
New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
